Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

98.62EUR
17 Sep 2019
Change (% chg)

€-0.88 (-0.88%)
Prev Close
€99.50
Open
€99.74
Day's High
€100.55
Day's Low
€98.62
Volume
480,705
Avg. Vol
458,712
52-wk High
€102.90
52-wk Low
€85.06

Latest Key Developments (Source: Significant Developments)

Merck KGaA Confirms 2019 Targets
Wednesday, 11 Sep 2019 

Sept 11 (Reuters) - Merck KGaA ::PERFORMANCE MATERIALS IS ON TRACK WITH ITS TRANSFORMATION PROGRAM AND EXPECTS TO RESUME ORGANIC GROWTH AS OF 2020.FOCUS ON RAPID DELEVERAGING AND STRINGENT COST DISCIPLINE.EXPECTS TO ACHIEVE SUSTAINABLE PROFITABLE GROWTH IN ALL THREE BUSINESS SECTORS IN THE COMING YEARS.FOR 2019, WE CONTINUE TO ASSUME THAT THE GROUP WILL INCREASE ALL ITS KEY FIGURES: SALES, EBITDA PRE AND EPS PRE.HAVE OUR SIGHTS FIRMLY SET ON PROFITABLE GROWTH FOR 2020 AND BEYOND.WILL FOCUS ON GENERATING CASH IN ORDER TO QUICKLY LOWER ITS POST-ACQUISITION DEBT.BY 2022, COMPANY AIMS TO ACHIEVE ADDITIONAL ANNUAL SALES OF AROUND € 2 BILLION WITH NEW MEDICINES AND IS IN LINE WITH PLAN.CORE BUSINESS WITH EXISTING MEDICINES BASIS FOR SUSTAINABLE GROWTH OF HEALTHCARE BUSINESS SECTOR, AIMING FOR SALES TO AT LEAST REMAIN STABLE.IN COMING YEARS, LIFE SCIENCE BUSINESS SECTOR PLANS TO DELIVER ANNUAL GROWTH OF 5% TO 8% PER YEAR.PERFORMANCE MATERIALS EXPECTED TO RESUME GROWTH AS OF 2020.AS OF 2020, MERCK ASSUMES THAT AVERAGE ANNUAL SALES GROWTH IN PERFORMANCE MATERIALS WILL RANGE BETWEEN 2% AND 3%.PERFORMANCE MATERIALS LONG-TERM EBITDA PRE MARGIN TARGET IS AROUND 30%.OLED MATERIALS BUSINESS IS SHOWING TREMENDOUS GROWTH DYNAMIC.  Full Article

GSK Announces Jack Bailey, President U.S. Pharmaceuticals, Decided To Step Down
Monday, 12 Aug 2019 

Aug 12 (Reuters) - GlaxoSmithKline PLC ::JACK BAILEY, PRESIDENT U.S. PHARMACEUTICALS HAS DECIDED TO STEP DOWN FROM ROLE AT END OF YEAR.BAILEY TO BE SUCCEEDED BY MAYA MARTINEZ-DAVIS.MARTINEZ-DAVIS TO JOIN GSK IN MID-SEPT AND WILL ASSUME RESPONSIBILITY OF THE U.S. PHARMACEUTICALS BUSINESS ON JAN 1, 2020.  Full Article

Merck Buys BSSN Software
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - MERCK KGAA ::ACQUIRES BSSN SOFTWARE.FINANCIAL DETAILS WERE NOT DISCLOSED.BSSN’S EMPLOYEES HAVE JOINED MERCK AS PART OF ITS APPLIED DIGITAL LAB PRODUCTIVITY SOLUTIONS TEAM.  Full Article

Intermolecular Stockholders Approve Merck KGaA, Darmstadt, Germany's Proposed Acquisition Of Intermolecular
Thursday, 18 Jul 2019 

July 17 (Reuters) - Intermolecular Inc ::INTERMOLECULAR STOCKHOLDERS APPROVE MERCK KGAA, DARMSTADT, GERMANY'S PROPOSED ACQUISITION OF INTERMOLECULAR.INTERMOLECULAR INC - MERCK KGAA'S PROPOSED ACQUISITION OF INTERMOLECULAR IS EXPECTED TO CLOSE IN SECOND HALF OF 2019.INTERMOLECULAR - HOLDERS OF ABOUT 72% OF INTERMOLECULAR'S OUTSTANDING COMMON STOCK VOTED IN FAVOR OF PROPOSED MERGER TRANSACTION WITH MERCK KGAA.  Full Article

Merck KGaA Says Has Placed 2 Billion EUR Worth Of Bonds To Fund Acquisition Of Versum Materials Inc.
Monday, 1 Jul 2019 

Merck Kgaa ::SAYS HAS PLACED 2 BILLION EUR WORTH OF BONDS TO FUND ACQUISITION OF VERSUM MATERIALS INC..  Full Article

Merck KGaA Affirms Versum Deal Expected To Close In Second Half
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Merck KGaA ::PLEASED THAT VERSUM STOCKHOLDERS HAVE VOTED IN FAVOR OF US MOVING FORWARD WITH THIS TRANSACTION.TRANSACTION IS EXPECTED TO CLOSE IN THE SECOND HALF OF 2019.  Full Article

Versum Materials Stockholders Approve Merger With Merck KGaA
Tuesday, 18 Jun 2019 

June 17 (Reuters) - Versum Materials Inc::VERSUM MATERIALS STOCKHOLDERS APPROVE MERGER WITH MERCK KGAA, DARMSTADT, GERMANY.VERSUM MATERIALS INC - VERSUM CONTINUES TO EXPECT TRANSACTION WITH MERCK KGAA TO CLOSE IN SECOND HALF OF 2019.  Full Article

Bioxcel Therapeutics Announces FDA Clearance Of IND Application
Monday, 3 Jun 2019 

June 3 (Reuters) - BioXcel Therapeutics Inc ::BIOXCEL THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR TRIPLE COMBINATION IN PANCREATIC CANCER AND CTA ACCEPTANCE FOR DOUBLE COMBINATION IN AGGRESSIVE FORM OF PROSTATE CANCER (TNEPC) FOR LEAD IMMUNO-ONCOLOGY PROGRAM, BXCL701.BIOXCEL THERAPEUTICS INC - MHRA ACCEPTS CLINICAL APPLICATION FOR DOUBLE COMBINATION TRIAL OF BXCL701 AND KEYTRUDA IN TNEPC PATIENTS.BIOXCEL - COLLABORATING WITH NEKTAR THERAPEUTICS, MERCK KGAA, PFIZER TO CONDUCT TRIAL TO EVALUATE TRIPLE COMBINATION OF BXCL701, BEMPEGALDESLEUKIN & AVELUMAB.  Full Article

Merck KGaA CFO Says No Concrete Plans At The Moment To Divest Any Businesses
Friday, 12 Apr 2019 

April 12 (Reuters) - Merck Kgaa analyst call::CFO SAYS NO SIZABLE TAKEOVER TRANSACTIONS PLANNED IN THE FORESEEABLE FUTURE AFTER VERSUM DEAL, DELEVERAGING IS FOCUS OVER NEXT COUPLE OF YEARS.CFO SAYS WANT TO KEEP A DIVERSIFIED 3 PILLAR STRUCTURE FOR THE COMPANY.CFO SAYS THERE ARE NO CONCRETE PLANS AT THE MOMENT TO DIVEST ANY BUSINESSES IN THE NEAR FUTURE.  Full Article

FDA Approves New Oral Treatment For Multiple Sclerosis
Saturday, 30 Mar 2019 

March 29 (Reuters) - Merck KGaA ::FDA APPROVES NEW ORAL TREATMENT FOR MULTIPLE SCLEROSIS.FDA - APPROVED MAVENCLAD TABLETS TO TREAT RELAPSING FORMS OF MS IN ADULTS, TO INCLUDE RELAPSING-REMITTING DISEASE & ACTIVE SECONDARY PROGRESSIVE DISEASE.FDA - GRANTED APPROVAL OF MAVENCLAD TO EMD SERONO INC.FDA - MAVENCLAD HAS A BOXED WARNING FOR AN INCREASED RISK OF MALIGNANCY AND FETAL HARM.FDA - MAVENCLAD IS NOT RECOMMENDED FOR MS PATIENTS WITH CLINICALLY ISOLATED SYNDROME.  Full Article

Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane

FRANKFURT, Sept 11 Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation.